Rogelio Braceras, MD: Improving Costs, Comorbidities in T2D

June 24, 2018 7:17 pm

The Boehringer Ingelheim representative discusses how the future of empagliflozin research should shape out.

Category: News
About The Author
-
Previous

Zanetti et al; Birthweight, T2D, and Cardiovascular Disease
Next

Reversing T2D with a keto diet — Diet Doctor Podcast with Dr. Sarah Hallberg

Related Videos

Mechanisms-of-Action-of-GLP-1-Agonists-in-T2D

Mechanisms of Action of GLP-1 Agonists in T2D

EASD-2019-Personalised-Prevention-Of-CVD-In-T2D-Prof-Alessandro-Doria

EASD 2019 : Personalised Prevention Of CVD In T2D- Prof Alessandro Doria

2038018

The Role of Nutrition in the Prevention and Intervention of Type 2 Diabetes

Diabetologists-Perspective-of-Diabetes-and-Cardiovascular-Risk-Management-in-Post-ACS-T2D-patients

Diabetologist’s Perspective of Diabetes and Cardiovascular Risk Management in Post-ACS T2D patients

Dr.-David-Unwin-The-Glycaemic-Index-Helping-Patients-in-Primary-care-with-T2D

Dr. David Unwin – ‘The Glycaemic Index: Helping Patients in Primary care with T2D’

Introduction-to-SGLT2-Inhibition

Introduction to SGLT2 Inhibition